Immune Profiling Core
免疫分析核心
基本信息
- 批准号:10649944
- 负责人:
- 金额:$ 26.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-15 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adjuvant TherapyAntibodiesAntigensAutopsyB-LymphocytesBiological AssayBiological Specimen BanksBiopsyBody FluidsCell DeathCellsChairpersonClinicalColorCommunicable DiseasesCore FacilityCryopreservationCytomegalovirusDiseaseEnvironmentFlow CytometryGoalsGraft RejectionHealthHistologyHumanHuman Herpesvirus 4ImmuneImmunityImmunizationImmunoassayImmunocompromised HostImmunohistochemistryImmunologicsImmunology procedureImmunosuppressionIndividualInfrastructureKidney TransplantationKnowledgeLaboratoriesLasersLeadLeadershipLymphocryptovirusMacaca mulattaManagement Information SystemsMemory B-LymphocyteMonitorOperative Surgical ProceduresOrganPatientsPeripheral Blood Mononuclear CellPhenotypePlasmaPlasma CellsPositioning AttributePre-Clinical ModelPrior TherapyProceduresProteasome InhibitionRegimenRegulationResearchResearch SupportResource SharingRhesusRiskSafetySamplingScientistSerumServicesSimian virus 40SirolimusSpecimenSpecimen HandlingStainsStandardizationStructure of germinal center of lymph nodeSupervisionT-LymphocyteTechnical ExpertiseTestingThymus GlandTissue SampleTissuesTransplantationTransplantation ImmunologyUniversitiesViralViral AntigensVirus LatencyWorkallotransplantbasebiobankclinically relevantcytokinedesensitizationdigitalexhaustionimprovedinstrumentkidney allograftlaboratory experiencelymph nodesmedical schoolsnonhuman primatenovel therapeutic interventionpost-transplantpreservationpreventprogramsquality assuranceresearch studysecondary lymphoid organside effectsingle cell analysissynergismtesting services
项目摘要
Immune Profiling Core The Immune Profiling Core (IPC) will provide comprehensive technical assay support services for the hypothesis-driven research studies proposed in the two Projects comprising this U19 proposal. The Core derives its greatest overall strength from the relevant expertise, organization, procedures, and operational synergy of its components. Anchoring these efforts is the Duke Immune Profiling Core (DIPC), a Duke School of Medicine Shared Resource that has been in existence since 1988. Largely focused on flow cytometry-based platforms for human immune profiling, the Core has actively participated in external proficiency testing and quality assurance programs for over 25 years. Assay testing is performed in a Good Clinical Laboratory (GCLP)-compliant environment according to highly standardized and validated Standard Operating Procedures (SOPs). The Core is joined in its efforts by a support team of highly experienced laboratory professionals from the Kirk and Knechtle research Cores who have recently re-located to Duke from Emory University. These individuals have extensive expertise in all aspects of transplantation research, both in human and nonhuman primate (NHP) studies. The key services the IPC will provide to Projects 1 and 2 include: 1) state-of-the-art specimen processing and biobanking, 2) analytical polychromatic flow cytometry (PFC) phenotyping, and intracellular cytokine staining (ICCS), 3) virologic testing, and 4) comprehensive histology and immunohistochemistry support. The IPC is well positioned to provide PFC services to the projects under this proposal; PFC having been the technical mainstay of the research endeavors of the DIPC. The present core facility houses a 4-laser BD LSRII, 5-laser BD LSRFortessa, 5-laser BD LSR-X20 and, most recently, a 5-laser BD LSR-X50. Of these digital instruments, the first 3 are capable of up to 18-24 parameter single cell analyses, while the X50 is capable of supporting 50-parameter flow cytometry. To provide comprehensive immunologic support, we have implemented several highly developed components for the IPC. A specimen processing and biobanking service that began at Emory under Dr. Kirk has been re-established as the Substrate Services and Research Support Service (SSCRSS) at Duke following his arrival as Chairman of the Department of Surgery. Through the work of Dr. Kirk's laboratory, we have also established a viral testing facility that will allow the IPC to monitor three of the most clinically-relevant latent viruses in NHPs: Rhesus Cytomegalovirus (rhCMV), Rhesus Lymphocryptovirus (rhLCV) (rhesus homology of EBV), and Simian Virus 40 (SV40). The IPC will provide routine histology and immunohistochemistry assays through our immunohistochemistry service laboratory, which will allow each project to examine the effects of the experimental manipulations on key host tissue. Special emphasis will be placed on examining effects on germinal center formation following the various induction regimens. The juxtaposition of human and NHP expertise represents a particular strength of this IPC consortium, further facilitating the highly translational aspects of the proposed studies
免疫分析核心免疫分析核心(IPC)将为由U19提案组成的两个项目中提出的假设驱动的研究提供全面的技术测定支持服务。核心从其组件的相关专业知识,组织,程序和运营协同作用中获得了最大的总体力量。杜克免疫分析核心(DIPC)是杜克大学医学学院共享资源,自1988年以来一直存在。主要集中在基于流式细胞仪的人类免疫分析的平台上,该核心已积极参与了25年以上的外部熟练度测试和质量保证计划。根据高标准化和经过验证的标准操作程序(SOP),在良好的临床实验室(GCLP)编译环境中进行测定测试。来自柯克和诺克特尔研究核心的经验丰富的实验室专业人员的支持团队加入了核心,他们最近从埃默里大学重新分配给了杜克大学。这些人在人类和非人类灵长类动物(NHP)研究的移植研究的各个方面都有广泛的专业知识。 IPC将向项目1和2提供的关键服务包括:1)最先进的标本处理和生物群,2)分析性多色流式细胞术(PFC)表型,以及细胞内细胞因子染色(ICCS),3)病毒学测试,以及4)综合组织学和免疫学组成症。 IPC在此提案下为项目提供PFC服务的好处; PFC是DIPC研究努力的技术中流tay柱。目前的核心设施设有4射线BD LSRII,5射线BD LSRFORTESSA,5-laser BD LSR-X20,以及最近的5射线BD LSR-X50。在这些数字仪器中,前3个最多能够进行18-24个参数单细胞分析,而X50能够支持50参数流式细胞仪。为了提供全面的免疫支持,我们为IPC实施了几个高度发展的组件。在柯克博士(Kirk)领导下的埃默里(Emory)的一项标本加工和生物群体服务已被重新建立为杜克大学(Duke)担任外科部董事长后的基板服务和研究支持服务(SSCRSS)。通过Kirk博士的实验室的工作,我们还建立了一个病毒测试设施,该设施将使IPC可以监测NHPS中最临床上最临床最重要的潜在病毒:恒河猴胞膜瘤病毒(RHCMV),瑞斯斯淋巴结病毒(rhlcv)(Rhlcv)(Rhlcv)(Rhelsus obv)和Simian Aimian病毒式40(SV)40(SV)40(SV)40( IPC将通过我们的免疫组织化学实验室提供常规的组织学和免疫组织化学测定,这将使每个项目都可以检查实验操纵对关键宿主组织的影响。在各种诱导方案之后,将特别强调检查对生发中心形成的影响。人类和NHP专业知识的并置代表了该IPC财团的特殊优势,进一步促进了拟议的研究的高度转化方面
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kent J. Weinhold其他文献
Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.
来自人类免疫缺陷病毒血清阳性供体的 IgG 静脉注射溶液的制备和表征。
- DOI:
10.1182/blood.v77.5.1111.bloodjournal7751111 - 发表时间:
1991 - 期刊:
- 影响因子:20.3
- 作者:
Larry M. Cummins;Kent J. Weinhold;Thomas J. Matthews;A. J. Langlois;C. F. Perno;RICHARD M. Condie;Jean - 通讯作者:
Jean
Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.
HIV 包膜糖蛋白中和单克隆抗体的特征。
- DOI:
- 发表时间:
1988 - 期刊:
- 影响因子:1.5
- 作者:
Michael A. Skinner;Robert Ting;A. J. Langlois;Kent J. Weinhold;H. K. Lyerly;K. Javaherian;Thomas J. Matthews - 通讯作者:
Thomas J. Matthews
3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase
3-叠氮基-3-脱氧胸苷三磷酸作为纯化人免疫缺陷病毒逆转录酶的抑制剂和底物
- DOI:
10.1128/aac.31.12.1972 - 发表时间:
1987 - 期刊:
- 影响因子:4.9
- 作者:
M. H. S. Clair;Cynthia A. Richards;Thomas Spector;Kent J. Weinhold;Wayne H. Miller;A. J. Langlois;Phillip A. Furman - 通讯作者:
Phillip A. Furman
Measurement of direct and indirect forms of anti-HIV-1 ADCC: implications for other retroviral disease.
抗 HIV-1 ADCC 的直接和间接形式的测量:对其他逆转录病毒疾病的影响。
- DOI:
- 发表时间:
1990 - 期刊:
- 影响因子:0
- 作者:
Kent J. Weinhold;Douglas S. Tyler;H. K. Lyerly - 通讯作者:
H. K. Lyerly
Coupling Hematoma Evacuation with Immune Profiling for Analysis of Neuroinflammation After Primary Intracerebral Hemorrhage: A Pilot Study
- DOI:
10.1016/j.wneu.2022.02.062 - 发表时间:
2022-05-01 - 期刊:
- 影响因子:
- 作者:
Jay B. Lusk;Quintin J. Quinones;Janet S. Staats;Kent J. Weinhold;Peter M. Grossi;Shahid M. Nimjee;Daniel T. Laskowitz;Michael L. James - 通讯作者:
Michael L. James
Kent J. Weinhold的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kent J. Weinhold', 18)}}的其他基金
Biorepository, Pathology, and Immune Monitoring Core
生物样本库、病理学和免疫监测核心
- 批准号:
10248315 - 财政年份:2014
- 资助金额:
$ 26.01万 - 项目类别:
Biorepository, Pathology, and Immune Monitoring Core
生物样本库、病理学和免疫监测核心
- 批准号:
10705239 - 财政年份:2014
- 资助金额:
$ 26.01万 - 项目类别:
相似国自然基金
抗变构/单体形式的C反应蛋白关键抗原表位199-206抗体在狼疮性肾炎小管间质病变中的作用机制及其靶向治疗研究
- 批准号:82300829
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
原位疫苗新策略:抗体偶联仿生ROS纳米酶增强巨噬细胞吞噬及抗原交叉呈递效应
- 批准号:32371454
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
基于抗原抗体相互作用的抗体定向虚拟设计与筛选
- 批准号:32370697
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
单个抗体IgG在图案化抗原阵列上运动的可视化研究
- 批准号:32301180
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
CD40-CD154共刺激信号介导的TD/TI抗原诱导罗非鱼抗体分泌细胞形成机制的比较研究
- 批准号:32303044
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 26.01万 - 项目类别:
A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection
预防淋病奈瑟菌感染的新型舌下疫苗
- 批准号:
10699065 - 财政年份:2023
- 资助金额:
$ 26.01万 - 项目类别:
Project 2: Mechanisms of Resistance to Neoantigen Vaccines in PDAC
项目2:PDAC新抗原疫苗耐药机制
- 批准号:
10708575 - 财政年份:2023
- 资助金额:
$ 26.01万 - 项目类别:
Validation of the joint-homing and drug delivery attributes of novel peptides in a mouse arthritis model
在小鼠关节炎模型中验证新型肽的关节归巢和药物递送特性
- 批准号:
10589192 - 财政年份:2023
- 资助金额:
$ 26.01万 - 项目类别:
Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer
确定早期三阴性乳腺癌的最佳放疗剂量和分割与术前免疫化疗相结合
- 批准号:
10512391 - 财政年份:2023
- 资助金额:
$ 26.01万 - 项目类别: